SK284503B6 - Prípravky obsahujúce oxakarbazepín, tableta potiahnutá filmom, spôsob jej výroby a oxakarbazepín - Google Patents

Prípravky obsahujúce oxakarbazepín, tableta potiahnutá filmom, spôsob jej výroby a oxakarbazepín Download PDF

Info

Publication number
SK284503B6
SK284503B6 SK1098-99A SK109899A SK284503B6 SK 284503 B6 SK284503 B6 SK 284503B6 SK 109899 A SK109899 A SK 109899A SK 284503 B6 SK284503 B6 SK 284503B6
Authority
SK
Slovakia
Prior art keywords
oxacarbazepine
weight
film
particle size
average particle
Prior art date
Application number
SK1098-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK109899A3 (en
Inventor
Burkhard Schl�Termann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4184588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK284503(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK109899A3 publication Critical patent/SK109899A3/sk
Publication of SK284503B6 publication Critical patent/SK284503B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
SK1098-99A 1997-02-14 1998-02-12 Prípravky obsahujúce oxakarbazepín, tableta potiahnutá filmom, spôsob jej výroby a oxakarbazepín SK284503B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH33197 1997-02-14
PCT/EP1998/000794 WO1998035681A1 (en) 1997-02-14 1998-02-12 Oxacarbazepine film-coated tablets

Publications (2)

Publication Number Publication Date
SK109899A3 SK109899A3 (en) 2000-03-13
SK284503B6 true SK284503B6 (sk) 2005-05-05

Family

ID=4184588

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1098-99A SK284503B6 (sk) 1997-02-14 1998-02-12 Prípravky obsahujúce oxakarbazepín, tableta potiahnutá filmom, spôsob jej výroby a oxakarbazepín

Country Status (32)

Country Link
US (2) US20070036863A1 (pt)
EP (1) EP0966287B1 (pt)
JP (3) JP2000511935A (pt)
KR (3) KR19980071337A (pt)
CN (2) CN1170542C (pt)
AR (1) AR011142A1 (pt)
AT (1) ATE239481T1 (pt)
AU (1) AU738030B2 (pt)
BR (1) BR9807368A (pt)
CA (1) CA2277791C (pt)
CO (1) CO4920215A1 (pt)
CY (1) CY2480B1 (pt)
CZ (1) CZ298840B6 (pt)
DE (1) DE69814367T2 (pt)
DK (1) DK0966287T3 (pt)
ES (1) ES2199422T3 (pt)
HK (1) HK1024423A1 (pt)
HU (1) HU227807B1 (pt)
ID (1) ID22348A (pt)
MY (1) MY117582A (pt)
NO (1) NO327486B1 (pt)
NZ (1) NZ336946A (pt)
PE (1) PE58999A1 (pt)
PL (1) PL193332B1 (pt)
PT (1) PT966287E (pt)
RU (1) RU2201218C2 (pt)
SK (1) SK284503B6 (pt)
TR (1) TR199901804T2 (pt)
TW (1) TW529957B (pt)
UY (1) UY24888A1 (pt)
WO (1) WO1998035681A1 (pt)
ZA (1) ZA981205B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
JP2005513099A (ja) 2001-12-21 2005-05-12 ファイザー・プロダクツ・インク アジスロマイシンの直接的に圧縮可能な配合品
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
SG146631A1 (en) 2003-09-03 2008-10-30 Novartis Ag Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
AR048672A1 (es) * 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
PE20051156A1 (es) * 2004-03-22 2006-02-13 Novartis Ag Formulaciones de matriz orales que comprenden licarbazepina
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
EP1928427B1 (en) 2005-09-23 2009-12-30 F.Hoffmann-La Roche Ag Novel dosage formulation
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
WO2007053904A1 (en) 2005-11-10 2007-05-18 Alphapharm Pty Ltd Process to control particle size
AU2006313009B2 (en) * 2005-11-10 2013-10-24 Alphapharm Pty Ltd Process to control particle size
EP2029118A2 (en) * 2006-01-31 2009-03-04 Teva Pharmaceutical Industries, Inc. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
AU2006337141A1 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
AU2007242062A1 (en) * 2006-04-21 2007-11-01 Alphapharm Pty Ltd Pharmaceutical compositions of oxcarbazepine with a median particle size of 15 to 30 microns
EP2018157A2 (en) 2006-04-26 2009-01-28 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
ATE496623T1 (de) * 2006-04-26 2011-02-15 Supernus Pharmaceuticals Inc Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil
US20080138403A1 (en) * 2006-12-08 2008-06-12 Sun Pharmaceutical Industries Ltd. Pharmaceutical dosage forms of oxcarbazepine
CA2673418A1 (en) 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical compound and composition
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
EP2146699A2 (en) * 2007-05-23 2010-01-27 Ratiopharm GmbH Pharmaceutical compositions comprising oxcarbazepine
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
CN103735527B (zh) * 2013-12-24 2014-09-10 武汉人福药业有限责任公司 一种奥卡西平片剂及其制备方法
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI75561C (fi) * 1979-10-30 1988-07-11 Ciba Geigy Ag Foerfarande foer framstaellning av 5- karbamoyl-10-oxo-10,11-dihydro-5h-dibens/b,f/azepin och daertill noedvaendiga mellanprodukter.
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
JPS6257467A (ja) * 1985-09-06 1987-03-13 Asahi Glass Co Ltd コ−テイング剤組成物
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
DD295760A5 (de) * 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5478654A (en) * 1994-05-06 1995-12-26 Gencorp Inc. Solventless carboxylated butadiene-vinylidene chloride adhesives for bonding rubber to metal
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones

Also Published As

Publication number Publication date
ID22348A (id) 1999-09-30
NO327486B1 (no) 2009-07-13
NO993919L (no) 1999-08-13
ES2199422T3 (es) 2004-02-16
US20080014269A1 (en) 2008-01-17
EP0966287B1 (en) 2003-05-07
KR19980071337A (ko) 1998-10-26
CZ298840B6 (cs) 2008-02-20
DK0966287T3 (da) 2003-08-25
SK109899A3 (en) 2000-03-13
TW529957B (en) 2003-05-01
CN1626093A (zh) 2005-06-15
BR9807368A (pt) 2000-03-14
JP2010132694A (ja) 2010-06-17
CZ287999A3 (cs) 1999-11-17
US20070036863A1 (en) 2007-02-15
NZ336946A (en) 2001-02-23
WO1998035681A1 (en) 1998-08-20
CO4920215A1 (es) 2000-05-29
PL334959A1 (en) 2000-03-27
JP2006077029A (ja) 2006-03-23
HUP0000886A3 (en) 2002-10-28
HU227807B1 (en) 2012-03-28
AU6622298A (en) 1998-09-08
DE69814367T2 (de) 2004-02-26
CY2480B1 (en) 2005-06-03
KR20120079826A (ko) 2012-07-13
CN1170542C (zh) 2004-10-13
CN1247471A (zh) 2000-03-15
AU738030B2 (en) 2001-09-06
TR199901804T2 (xx) 1999-09-21
PL193332B1 (pl) 2007-02-28
HK1024423A1 (en) 2000-10-13
EP0966287A1 (en) 1999-12-29
NO993919D0 (no) 1999-08-13
ZA981205B (en) 1998-08-14
KR20090037873A (ko) 2009-04-16
ATE239481T1 (de) 2003-05-15
DE69814367D1 (de) 2003-06-12
MY117582A (en) 2004-07-31
CA2277791A1 (en) 1998-08-20
JP2000511935A (ja) 2000-09-12
HUP0000886A2 (hu) 2000-09-28
PT966287E (pt) 2003-09-30
CA2277791C (en) 2008-11-18
UY24888A1 (es) 2000-12-29
AR011142A1 (es) 2000-08-02
RU2201218C2 (ru) 2003-03-27
PE58999A1 (es) 1999-06-25

Similar Documents

Publication Publication Date Title
SK284503B6 (sk) Prípravky obsahujúce oxakarbazepín, tableta potiahnutá filmom, spôsob jej výroby a oxakarbazepín
AU777705B2 (en) Pharmaceutical compositions
CA2131495C (en) Double-layered oxcarbazepine tablets
US7037525B2 (en) Oxacarbazepine film-coated tablets
AU2007263261B2 (en) Galenical formulations of aliskiren and hydrochlorothiazide
WO2009026621A1 (en) Pharmaceutical compound & composition
NZ509391A (en) Oxacarbazepine film-coated tablets further comprising a hydrophobic permeable outer coating containing iron oxide from 0.3 to 0.9 mg per tablet
MXPA99007514A (en) Oxacarbazepine film-coated tablets

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20140212